sellWeak cluster of 210b5-1 plan
Richard A Colvin sold $1,178 of BLUE
Chief Medical Officer at bluebird bio, Inc.. 2,824 shares at an average of $0.42, traded Dec 10, 2024, filed Dec 12, 2024.
Warning score
3Value
$1,178
2,824 shares
Holdings after
165,544
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$1k at market
- 0Share of holdings soldSold 1.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-24-008361, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 10, 2024 | SOpen-market sale Common Stock10b5-1 | -2,824 | $0.42 | $1,178 | 165,544 | Dec 12, 2024 |
Related signals
Other insiders at bluebird bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $2,289 584 shares | -7% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $1,960 500 shares | -6% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $473 64 shares | -1% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $902 122 shares | -1% | |
| 0Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $176 19 shares | -0% | |
| 13Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $405 971 shares | -0% | |
| 2Weak | bluebird bio, Inc. | Christopher Krawtschuk Chief Financial Officer | $20k 4,526 shares | -9% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $6,975 2,343 shares | -2% | |
| 13Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $2,555 807 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.